Hopp til hovedinnhold

Guillain-Barré syndrom (AIDP)

Sist revidert:
Sist revidert av:

Definisjon:
Akutt perifer polynevropati av autoimmun årsak. Oftest forutgått av infeksjonssykdom.
Forekomst:
1-2 tilfeller per 100.000 personer per år
Symptomer:
Akutt innsettende svakhetsfølelse, nummenhet, parestesier og smerter i ekstremiteter, symmetrisk lokalisert
Funn:
Pareser og svekkede reflekser, nedsatt perifer sensibilitet.
Diagnostikk:
Klinisk diagnose, men bekreftes ved måling av nerveledning
Behandling:
Sykehusinnleggelse med overvåkning av vitale funksjoner. Likeverdige behandlingsalternativer er intravenøs immunglobulin eller plasmaferese.
  1. Walling AD, Dickson G. Guillain-Barré syndrome. Am Fam Physician 2013; 87: 191-7. American Family Physician  
  2. Leonard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology 2019; 15: 671–683 .
  3. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Seminar. Lancet 2021; 397: 1214-28. doi:10.1016/S0140-6736(21)00517-1 DOI  
  4. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36: 123-33. PubMed  
  5. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27. Epub 2016 Mar 2. pmid: 2694843 PubMed  
  6. Koga M, Takahashi M, Masuda M, Hirata K, Yuki N. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. Neurology. 2005 Nov 8. 65(9):1376-81.
  7. Rocha Cabrero F, Morrison EH. Miller Fisher syndrome. 2021. In StatPearls. Treasure Island, FL StatPearls Publishing 2021. www.ncbi.nlm.nih.gov  
  8. Hughes RAC, Swan AV, Raphaël JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130: 2245-57. PubMed  
  9. Rudolph T, Larsen JP, Farbu E. The long-term functional status in patients with Guillain-Barré syndrome. Eur J Neurol. 2008 Dec. 15(12):1332-7.
  10. Cohen V, Arnulf I, Demeret S, et al. Vivid dreams, hallucinations, psychosis and REM-sleep in Guillain-Barré syndrome. Brain 2005; 128: 2535-45. PubMed  
  11. Nobuhiro Y, Hartung H-P. Guillain-Barré syndrome. N Engl J Med 2012; 366: 2294-304. New England Journal of Medicine  
  12. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 2001; 58: 913-7. PubMed  
  13. Winer JB. Guillain-Barre syndrom. Clinical review. BMJ 2008; 337: a671. PubMed  
  14. Gorson KC, Ropper AH, Muriello MA, et al. Prospective evaluation of MRI lumbosacral root enhancement in acute Guillain–Barré syndrome. Neurology 1996; 47: 813–17.
  15. Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 736-40. Neurology  
  16. Vriesendorp FJ. Guillain-Barré syndrome in adults: Clinical features and diagnosis. UpToDate, last updated Dec 04, 2018. UpToDate  
  17. Gerdts R, Jensen D, Fauchald P, Skjeldal O, Guillain-Barré Syndrome. Moderne behandlingsprinsipper belyst ved et klinisk materiale, Tidsskr Nor lægeforen 1999; 119: 506-9
  18. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2014, Issue 9. Art. No.: CD002063. DOI: 10.1002/14651858.CD002063.pub6. DOI  
  19. Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD001798. DOI: 10.1002/14651858.CD001798.pub2. DOI  
  20. Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016 Oct 24;10:CD001446 . pmid:27775812 PubMed  
  21. van Koningsveld R, Schmitz PIM, van der Meché FGA, et al. Effect of methylprednisolone when added to standard treatement with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004; 363: 192-6. PubMed  
  22. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. The Italian Guillain-Barré Study Group. Brain 1996; 119(pt 6): 2053-61.
  23. Korinthenberg R, Monting JS. Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study. Arch Dis Child 1996; 74: 281. PubMed  
  24. NevroNEL. Guillain-Barré syndrom. Norsk Nevrologisk Forening. Sist oppdatert sept. 2020. Siden lest 07.04.2021 nevrologi.legehandboka.no  
  25. Lawn ND, Wijdicks EF. Fatal Guillain-Barré syndrome. Neurology 1999; 52: 635-8. Neurology  
  26. Khan F, Pallant JF, Ng L, Bhasker A. Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome. J Neurol. 2010 Dec. 257(12):2024-31.
  27. Das A, Kalita J, Misra UK. Recurrent Guillain Barre' syndrome. Electromyogr Clin Neurophysiol. 2004 Mar. 44(2):95-102.
  • Rune Midgard, dr. med., overlege og førsteamanuensis II emeritus, NTNU
  • Ingard Løge, spesialist allmennmedisin, Trondheim

Tidligere fagmedarbeidere

  • Espen Dietrichs, professor og avdelingsoverlege, Universitetet i Oslo og Nevrologisk avdeling, Rikshospitalet, Oslo